Investing.com - Galera (NASDAQ: GRTX) reported third quarter EPS of $-0.330, $0.07 better than the analyst estimate of $-0.397. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Galera (NASDAQ: GRTX) reported second quarter EPS of $-0.480, $0.08 worse than the analyst estimate of $-0.404. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Galera (NASDAQ: GRTX) reported first quarter EPS of $-0.500, $0.12 worse than the analyst estimate of $-0.385. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Galera (NASDAQ: GRTX) reported first quarter EPS of $-0.580, $0.07 worse than the analyst estimate of $-0.507. Revenue for the quarter came in at $0.00 versus the...
By Davit Kirakosyan EF Hutton initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy rating and a price target of $304.00. The company announced that the U.S....
Investing.com - Galera reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations. Galera announced earnings per...
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Technology, Industrials and Utilities sectors led shares lower. At the close in NYSE, the Dow...
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to...
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that...